|
Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile? |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Roche |
|
|
Stock and Other Ownership Interests - Sirtex Medical |
Consulting or Advisory Role - sun biopharma |
Research Funding - Amgen (Inst); Bayer (Inst); Celgene (Inst); pfizer (Inst) |
|
|
Travel, Accommodations, Expenses - Amgen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ipsen; Roche; Shire |
Research Funding - Ipsen (Inst); Merck Serono (Inst) |
Travel, Accommodations, Expenses - Ipsen; Merck Serono; Roche |
|
|
Consulting or Advisory Role - Novartis |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst) |
Travel, Accommodations, Expenses - Medivation/Pfizer |